Genflow Biosciences Raises £500K to Progress Dog Aging Study

 

Genflow Biosciences Plc (LSE:GENF) has secured £500,000 in funding through a new share subscription, earmarked to support the next phase of its canine longevity study. The trial, which is investigating the safety and potential benefits of the company’s therapeutic candidate in older dogs, aims to enhance muscle strength and reduce biological markers associated with aging. With 24 senior dogs now randomized into the study, Genflow is making tangible progress toward its goal of advancing age-related research with implications for both veterinary and human health.

This latest funding highlights Genflow’s strategic focus on translating longevity science into real-world applications, underscoring its role as an innovator in the emerging field of age-targeting therapies.

About Genflow Biosciences Plc

Founded in 2020, Genflow Biosciences Plc is a UK-based biotechnology company with research operations in Belgium. The company is pioneering gene therapy solutions designed to slow aging, with its lead candidate, GF-1002, targeting the SIRT6 gene to support healthier, longer lives. Genflow is preparing for human clinical trials in 2025, beginning with treatments for MASH (Metabolic dysfunction-associated steatohepatitis), a widespread chronic liver condition.

• Average Daily Trading Volume: 2,083,956

• Technical Sentiment: Sell

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Envion

• 

  Anton F Balint

• 

  mattcollom

• 

  Kiana Danial